Ultima Genomics

Ultima Genomics

High-throughput genomic sequencing services

About Ultima Genomics

Simplify's Rating
Why Ultima Genomics is rated
A+
Rated A on Competitive Edge
Rated A on Growth Potential
Rated A+ on Differentiation

Industries

Biotechnology

Healthcare

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$604.2M

Headquarters

Newark, New Jersey

Founded

2016

Overview

Ultima Genomics improves human health through advanced genomic sequencing technologies, processing large volumes of genetic data to provide insights into biology and diseases. Its unique sequencing architecture allows for extensive data collection, detection of small genetic variations, and routine testing for early disease detection. This focus on breadth, depth, and frequency sets Ultima Genomics apart from competitors, providing clients with high-quality genomic information. The company's goal is to enable breakthroughs in understanding and treating diseases.

Simplify Jobs

Simplify's Take

What believers are saying

  • UG 100 Solaris platform reduces sequencing costs by 20%, increasing accessibility.
  • Partnerships with Myriad and NeoGenomics expand clinical applications in oncology and genomics.
  • Increased demand for single-cell sequencing drives collaborations like the Billion Cells Project.

What critics are saying

  • Competition from Illumina threatens Ultima's market share in genomic sequencing.
  • Rapid AI advancements by AWS and Compugen may outpace Ultima's technology.
  • Psomagen's collaboration with Chan Zuckerberg Initiative may divert clients from Ultima.

What makes Ultima Genomics unique

  • Ultima Genomics offers ultra-high-throughput sequencing with the UG 100 platform.
  • The company excels in breadth, depth, and frequency of genomic data collection.
  • Ultima's technology supports groundbreaking projects like the UK Biobank proteomics study.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$604.2M

Above

Industry Average

Funded Over

2 Rounds

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Holidays

Paid Vacation

Employee Assistance Program

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↓ -1%
PR Newswire
May 5th, 2025
Psomagen Selected As Key Service Provider, Will Utilize Ultima Genomics' Ug 100™ Sequencer To Accelerate Chan Zuckerberg Initiative'S Billion Cells Project

ROCKVILLE, Md., May 5, 2025 /PRNewswire/ -- Psomagen Inc., a multiomics service laboratory serving academic, pharma, biotech, and clinical customers, will join the Billion Cells Project led by the Chan Zuckerberg Initiative (CZI). The Billion Cells Project aims to develop a landmark single-cell dataset of one billion cells that will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function. Psomagen has begun providing services to participating researchers in April. The project includes collaborations with several other technology partners, including Ultima Genomics, 10x Genomics and Scale Biosciences. Su Hong, CEO of Psomagen, says, "This project represents a transformative step in biomedical research, enabling the identification of novel therapeutic targets and guiding drug development with unparalleled precision. By leveraging AI-powered analysis on vast single-cell datasets, we aim to accelerate the discovery of new ways to restore diseased cells to health

BioPharmaTrend
Apr 29th, 2025
NeoGenomics Adopts Ultima Genomics Platform to Expand Sequencing-Based Oncology Diagnostics

NeoGenomics has partnered with Ultima Genomics to integrate the UG 100 sequencing platform into its Cambridge, UK innovation center, aiming to develop a new range of clinical oncology tests.

HTXT
Apr 9th, 2025
How AI is being used to find a cure for Parkinson's Disease

Here, AWS is working with the likes of California-based company Ultima Genomics, which has developed software, algorithms and training of its AI models on AWS for its next-generation DNA sequencer.

Duniata
Apr 6th, 2025
Ultima genomics offers 3 trillion free sequencing reads to support the scientific community

Ultima Genomics, developer of an ultra-high-throughput sequencing architecture, today announced the launch of its "Count on Us" initiative.

PR Newswire
Feb 26th, 2025
Ultima Genomics Increases Output By Over 50% And Lowers Sequencing Costs By A Further 20% With The Introduction Of Ug 100 Solaris(Tm)

Commercial launch of UG 100 Solaris which includes new chemistry, software, and simplified workflows for the UG 100 sequencing platform, now with expanded applications support and integration with leading 'omics' technologies. Over 50% increase in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. Increased sensitivity with 5X yield improvement for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA (1/5th of the cfDNA found in a standard tube of blood)

Recently Posted Jobs

Sign up to get curated job recommendations

Ultima Genomics is Hiring for 7 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →